Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Andrew H who wrote (12861)	12/30/1997 9:38:00 PM
From: Henry Niman	Read Replies (2) \| Respond to of 32384

A Phase III protocol comparing Panretin to tretinoin (Vesinoid) to treat APL has appeared. The following centers are participating: George Ross Langley, Principal Investigator, Ph: 902-428-2107 Victoria General Hospital Halifax, Nova Scotia, Canada Wilson Miller, Jr., Principal Investigator, Ph: 514-340-8248 Jewish General Hospital Montreal, Quebec, Canada Raymond Taetle, Principal Investigator, Ph: 520-626-7228 Arizona Cancer Center Tucson, Arizona, USA Arturo Molina, Principal Investigator, Ph: 818-359-8111 ext 3973 Beckman Research Institute of the City of Hope Duarte, California, USA Dorothy Park, Principal Investigator, Ph: 310-855-4502 Cedars-Sinai Medical Center Los Angeles, California, USA Anthony D. Ho, Principal Investigator, Ph: 619-822-0400 University of California San Diego Cancer Center - La Jolla La Jolla, California, USA Dan Douer, Principal Investigator, Ph: 213-764-3950 USC/Norris Comprehensive Cancer Center Los Angeles, California, USA Stanley Raban Frankel, Principal Investigator, Ph: 202-687-2242 Vincent T. Lombardi Cancer Research Center, Georgetown University Medical Center Washington, District of Columbia, USA Martin Stuart Tallman, Principal Investigator, Ph: 312-908-8697 Northwestern University Robert H. Lurie Cancer Center Chicago, Illinois, USA Larry D. Cripe, Principal Investigator, Ph: 317-274-3545 Indiana University Cancer Center Indianapolis, Indiana, USA Glenn M. Mills, Principal Investigator, Ph: 318-675-5970 Louisiana State University Hospital - Shreveport Shreveport, Louisiana, USA Kenneth B. Miller, Principal Investigator, Ph: 617-956-5144 New England Medical Center Boston, Massachusetts, USA Laurence Elias, Principal Investigator, Ph: 505-277-5837 University of New Mexico Cancer Research & Treatment Center Albuquerque, New Mexico, USA Peter H. Wiernik, Principal Investigator, Ph: 718-920-4826 Albert Einstein Cancer Research Center - Bronx Bronx, New York, USA Raymond Paul Warrell, Jr., Principal Investigator, Ph: 212-639-8168 Memorial Sloan-Kettering Cancer Center New York, New York, USA Janet Cuttner, Principal Investigator, Ph: 212-241-6481 Mount Sinai Medical Center, NY New York, New York, USA Thomas C. Shea, Principal Investigator, Ph: 919-966-7746 Lineberger Comprehensive Cancer Center UNC Chapel Hill, North Carolina, USA Brenda W. Cooper, Principal Investigator, Ph: 216-844-3213 Case Western Reserve University/Ireland Cancer Center Cleveland, Ohio, USA William S. Velasquez, Principal Investigator, Ph: 409-772-1164 University of Texas Medical Branch Galveston, Texas, USA